Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Original ArticlesChronic Kidney Disease
You have accessRestricted Access

Cardiovascular Disease Among Hispanics and Non-Hispanics in the Chronic Renal Insufficiency Cohort (CRIC) Study

Ana C. Ricardo, James P. Lash, Michael J. Fischer, Claudia M. Lora, Matthew Budoff, Martin G. Keane, John W. Kusek, Monica Martinez, Lisa Nessel, Thomas Stamos, Akinlolu Ojo, Mahboob Rahman, Elsayed Z. Soliman, Wei Yang, Harold I. Feldman and Alan S. Go
CJASN September 2011, 6 (9) 2121-2131; DOI: https://doi.org/10.2215/CJN.11341210
Ana C. Ricardo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James P. Lash
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J. Fischer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claudia M. Lora
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew Budoff
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin G. Keane
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John W. Kusek
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Monica Martinez
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisa Nessel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Stamos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Akinlolu Ojo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mahboob Rahman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elsayed Z. Soliman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wei Yang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harold I. Feldman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan S. Go
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Prevalence of coronary artery calcium scores (0, 1 to 100, >100 to 400, >400) by race/ethnicity among participants with eGFR <30ml/min/1.73m2 (1a) and diabetes (1b). NH, non-Hispanic.

Tables

  • Figures
    • View popup
    Table 1.

    Baseline characteristics of participants

    Demographic CharacteristicsOverall (n = 3785)Hispanic (n = 497)Non-Hispanic Caucasian (n = 1638)P1Non-Hispanic African American (n = 1650)P2
    Age, years58.2 (11)56.3 (12)58.9 (11)<0.0158.1 (11)<0.01
    Gender, n (%)<0.01
        Male2076 (55)288 (58)982 (60)0.43806 (49)
        Female1709 (45)209 (42)656 (40)844 (51)
    Annual household income, n (%)<0.01<0.01
        <$20,0001213 (32)313 (63)254 (16)646 (39)
        $20,001–$50,000925 (24)92 (19)416 (25)417 (25)
        $50,001–$100,000694 (18)24 (5)455 (28)215 (13)
        >$100,000369 (10)12 (2)295 (18)62 (4)
        Missing584 (15)56 (11)218 (13)310 (9)
    Education, n (%)<0.01<0.01
        <7th grade210 (6)183 (37)7 (0.4)20 (1.2)
        7th to 12th grade610 (16)110 (22)83 (5)417 (25)
        High school diploma728 (19)71 (14)291 (18)366 (22)
        Some college1112 (29)78 (16)467 (29)567 (34)
        College graduate1125 (30)55 (11)790 (48)280 (17)
    Health insurance, n (%)<0.01<0.01
        Yes3085 (82)322 (65)1442 (88)1321 (80)
        No256 (7)113 (23)48 (3)95 (6)
        Missing444 (12)62 (12)148 (9)234 (14)
    Ever seen a nephrologist2503 (66)265 (53)1131 (69)<0.011107 (67)<0.01
    Kidney function measures
        Serum creatinine, mg/dl1.75 (0.6)1.88 (0.6)1.59 (0.5)<0.011.9 (0.6)0.77
        eGFR, ml/min/1.73 m242.8 (13)37.5 (13)43.7 (13)<0.0143.5 (14)<0.01
    eGFR categories, ml/min/1.73 m2, n (%)
        <30734 (19)151 (30)278 (17)<0.01305 (18)<0.01
        30 to <40939 (25)162 (33)389 (24)388 (24)
        40 to <50999 (26)107 (22)462 (28)430 (26)
        50 to <60722 (19)51 (10)349 (21)322 (20)
        >60391 (10)26 (5)160 (10)205 (12)
    24-hour urine protein, g, median (IQR)0.18 (0.1–0.9)0.72 (0.1–3.3)0.12 (0.1–0.5)<0.010.24 (0.1–1.1)<0.01
    Traditional cardiovascular risk factors
        Current cigarette smoker, n (%)504 (13)29 (6)155 (9)0.01320 (19)<0.01
        Hypertension, n (%)3269 (86)443 (89)1293 (79)<0.011533 (93)0.01
        Systolic BP, mmHg129 (22)136 (24)122 (19)<0.01133 (23)0.01a
        Diastolic BP, mmHg72 (13)73 (13)69 (11)<0.0174 (14)0.07
        Diabetes mellitus, n (%)1831 (48)334 (67)649 (40)<0.01848 (51)<0.01
        Hemoglobin A1C6.7 (2)7 (2)6.3 (1)<0.016.9 (2)0.29
        BMI, kg/m232 (8)32 (7)31 (8)0.2033 (8)<0.01
        Total cholesterol, mg/dl184 (45)189 (54)180 (42)<0.01a186 (46)0.14
        LDL cholesterol, mg/dl103 (36)104 (40)99 (32)0.03a106 (37)0.24
        HDL cholesterol, mg/dl48 (15)43 (13)47 (15)<0.0149 (16)<0.01
        Family history of premature CHD, n (%)603 (16)50 (10)322 (20)<0.01231 (14)0.02
    Nontraditional cardiovascular risk factors
        Hemoglobin, g/dl12.6 (2)12.1 (2)13.2 (2)<0.0112.2 (2)0.19
        Serum calcium corrected for albumin,b mg/dl9.2 (0.5)9.2 (0.4)9.2 (0.4)0.569.3 (0.5)0.01
        Serum phosphorus, mg/dl3.7 (0.7)4 (0.7)3.6 (0.6)<0.013.8 (0.7)<0.01
        Total iPTH, pg/ml, median (IQR)54 (35–90)62 (41–102)43 (30–69)<0.01a67 (41–115)0.09
        hs-CRP, mg/dl, Median (IQR)2.6 (1.1–6.6)2.5 (1.0–5.7)2.15 (0.9–5.2)0.263.3 (1.3–8.2)<0.01
    • Values indicate mean (standard deviation) unless otherwise specified. eGFR, estimated glomerular filtration rate; hs-CRF, high-sensitivity C-reactive protein; IQR, interquartile range; P1, Hispanic versus Non-Hispanic Caucasian; P2, Hispanic versus Non-Hispanic African American.

    • a No longer significant after adjustment for age, gender, education, eGFR.

    • b Corrected calcium = Measured serum calcium + [0.8*(4–serum albumin)].

    • View popup
    Table 2.

    Prevalence of cardiovascular disease (CVD)*

    VariablesOverall (n = 3785)Hispanic (n = 497)Non-Hispanic Caucasian (n = 1638)P1Non-Hispanic African American (n = 1650)P2
    Self-reported history of CVD
        Any CVD1272 (34)138 (28)507 (31)0.18627 (38)<0.01
        CHD (MI or coronary revascularization)827 (22)90 (18)376 (23)0.02361 (22)0.07
        Heart failure371 (10)37 (7)117 (7)0.82217 (13)<0.01
        Stroke382 (10)37 (7)118 (7)0.86227 (14)<0.01
        Peripheral arterial disease257 (7)35 (7)105 (6)0.62117 (7)0.97
    Subclinical Measures of CVD
        CAC score >100719 (37)115 (34)359 (41)0.03245 (35)0.88
        CAC score >400415 (22)65 (19)225 (26)0.02125 (18)0.52
        Left ventricular hypertrophy1663 (54)282 (71)538 (40)<0.01843 (63)<0.01
        Ankle-brachial index <0.9611 (16)72 (15)206 (13)0.23333 (20)<0.01
    • * Values indicate n (%) unless otherwise specified. CAC, coronary artery calcium score; IQR, interquartile range; P1, Hispanic versus non-Hispanic Caucasian; P2, Hispanic versus non-Hispanic African American.

    • View popup
    Table 3.

    Clinical and subclinical measures of cardiovascular disease by estimated glomerular filtration rate (eGFR) in ml/min/1.73 m2*

    eGFR, ml/min/1.73m2HispanicNon-Hispanic CaucasianP1Non-Hispanic African AmericanP2
    Self-reported Cardiovascular Disease, n (%)
        <3042 (28)115 (41)<0.01135 (44)<0.01
        30 to <4052 (32)143 (37)0.30174 (45)<0.01
        40 to <5030 (28)154 (33)0.29165 (38)0.05
        50 to <6010 (20)75 (21)0.76106 (33)0.06
        ≥604 (15)20 (13)0.6847 (23)0.38
    Coronary artery calcium score >100, n (%)
        <3032 (32)61 (53)<0.0147 (46)0.05
        30 to <4043 (38)91 (50)0.0543 (34)0.44
        40 to <5026 (34)99 (41)0.2569 (35)0.80
        50 to <6011 (33)83 (35)0.8159 (36)0.75
        ≥603 (18)25 (23)0.6027 (22)0.67
    Coronary artery calcium score >400, n (%)
        <3018 (18)37 (32)0.0228 (27)0.12
        30 to <4024 (21)61 (34)0.0327 (21)0.95
        40 to <5014 (18)61 (25)0.2031 (16)0.65
        50 to <607 (21)52 (22)0.9027 (17)0.52
        ≥602 (12)14 (13)0.8812 (10)0.80
    Left ventricular hypertrophy, n (%)
        <30104 (83)121 (54)<0.01182 (76)0.14
        30 to <4090 (70)139 (45)<0.01223 (69)0.72
        40 to <5057 (63)151 (40)<0.01219 (63)0.92
        50 to <6024 (65)93 (31)<0.01141 (54)0.20
        ≥607 (37)34 (25)0.2678 (45)0.48
    Ankle-brachial index <0.9, n (%)
        <3035 (24)53 (20)0.3086 (28)0.31
        30 to <4023 (15)68 (18)0.3784 (22)0.05
        40 to <505 (5)51 (11)0.0588 (21)<0.01
        50 to <607 (14)32 (9)0.2662 (19)0.39
        ≥602 (8)2 (1)0.0413 (7)0.82
    • * Values indicate n (%). P1, Hispanic versus non-Hispanic Caucasian; P2, Hispanic versus non-Hispanic African American.

    • View popup
    Table 4.

    Crude and adjusted odds ratio (OR) of clinical and subclinical measures of cardiovascular disease (CVD)

    VariablesAny self-reported CVDCAC >100CAC >400LVHABI <0.9
    OR (95% CI)P valueOR (95% CI)P valueOR (95% CI)P valueOR (95% CI)P valueOR (95% CI)P value
    Unadjusted
        Hispanic versus NH Caucasian0.86 (0.69, 1.07)0.180.75 (0.58, 0.97)0.030.69 (0.51, 0.94)0.023.64 (2.86, 4.63)<0.011.19 (0.89, 1.60)0.23
        Hispanic versus NH African American0.63 (0.50, 0.78)<0.010.98 (0.74, 1.29)0.881.11 (0.80, 1.55)0.521.44 (1.13, 1.83)<0.010.68 (0.52, 0.90)<0.01
    Adjusted for demographic characteristicsa
        Hispanic versus NH Caucasian1.10 (0.75, 1.62)0.630.89 (0.47, 1.69)0.731.12 (0.56, 2.24)0.742.16 (1.42, 3.27)<0.011.26 (0.79, 2.03)0.33
        Hispanic versus NH African American0.88 (0.61, 1.28)0.511.45 (0.77, 2.74)0.252.34 (1.17, 4.68)0.021.08 (0.71, 1.62)0.720.88 (0.56, 1.39)0.60
    Adjusted for demographic and clinical characteristicsb
        Hispanic versus NH Caucasian1.03 (0.68, 1.55)0.900.63 (0.30, 1.33)0.230.86 (0.39, 1.93)0.721.97 (1.22, 3.17)<0.011.29 (0.78, 2.13)0.32
        Hispanic versus NH African American0.82 (0.55, 1.23)0.341.35 (0.64, 2.82)0.432.49 (1.11, 5.58)0.031.44 (0.90, 2.31)0.131.05 (0.65, 1.70)0.84
        Age1.06 (1.05, 1.07)<0.011.10 (1.08, 1.11)<0.011.09 (1.07, 1.11)<0.011.03 (1.02, 1.04)<0.011.05 (1.04, 1.07)<0.01
        Gender (female versus male)0.66 (0.54, 0.79)<0.010.32 (0.24, 0.42)<0.010.36 (0.26, 0.50)<0.010.86 (0.70, 1.06)0.151.03 (0.81, 1.29)0.83
    Education
        <7th grade versus college graduate1.20 (0.75, 1.91)0.450.72 (0.37, 1.40)0.300.83 (0.39, 1.73)0.612.50 (1.37, 4.53)<0.011.12 (0.63, 1.99)0.70
        7th to 12th grade versus college graduate1.23 (0.94, 1.60)0.131.18 (0.75, 1.84)0.501.47 (0.90, 2.40)0.131.70 (1.24, 2.33)<0.011.49 (1.07, 2.08)0.02
        HS diploma versus college graduate1.29 (1.01, 1.64)0.041.37 (0.94, 1.98)0.101.58 (1.05, 2.38)0.031.44 (1.10, 1.88)<0.011.54 (1.13, 2.09)<0.01
        Some college versus college graduate1.38 (1.12, 1.71)<0.011.18 (0.86, 1.62)0.301.05 (0.73, 1.50)0.801.35 (1.07, 1.70)0.011.34 (1.00, 1.78)0.05
    eGFR (10 ml/min/1.73 m2 increase)0.90 (0.84, 0.97)<0.010.89 (0.79, 1.00)0.050.95 (0.82, 1.09)0.450.86 (0.79, 0.93)0.020.78 (0.71, 0.86)<0.01
    Proteinuria (natural log)1.08 (1.01, 1.15)0.021.03 (0.93, 1.13)0.581.06 (0.95, 1.18)0.281.17 (1.09, 1.26)<0.010.95 (0.88, 1.02)0.17
    Diabetes (yes versus no)1.63 (1.37, 1.95)<0.012.67 (2.02, 3.51)<0.012.08 (1.52, 2.83)<0.011.03 (0.84, 1.25)0.811.76 (1.40, 2.21)<0.01
    Hyperlipidemia (yes versus no)2.26 (1.76, 2.90)<0.011.69 (1.21, 2.37)<0.011.93 (1.25, 2.97)<0.011.09 (0.86, 1.39)0.482.04 (1.46, 2.84)<0.01
    BMI1.01 (1.00, 1.02)0.291.01 (0.99, 1.03)0.471.00 (0.98, 1.02)0.951.15 (1.13, 1.17)<0.011.00 (0.99, 1.02)0.77
    Systolic BP (10-mmHg increase)1.01 (0.97, 1.05)0.801.07 (1.00, 1.14)0.051.05 (0.97, 1.12)0.231.21 (1.15, 1.28)<0.011.06 (1.01, 1.12)0.02
    Current smoker (yes versus no)1.33 (1.06, 1.69)0.021.56 (1.03, 2.35)0.031.43 (0.90, 2.28)0.131.43 (1.09, 1.89)0.012.19 (1.67, 2.88)<0.01
    Family history of premature CHD1.80 (1.46, 2.20)<0.011.84 (1.33, 2.56)<0.011.91 (1.34, 2.73)<0.011.27 (0.99, 1.62)0.061.16 (0.90,1.51)0.25
    Serum hemoglobin0.96 (0.91, 1.01)0.140.91 (0.83, 0.99)0.030.87 (0.79, 0.95)<0.010.87 (0.82, 0.93)<0.010.97 (0.91, 1.04)0.45
    hs-CRP (1 SD)1.03 (0.96, 1.12)0.401.00 (0.85, 1.16)0.950.97 (0.81, 1.16)0.711.00 (0.91, 1.09)0.921.12 (1.03, 1.22)<0.01
    Serum phosphate1.06 (0.93, 1.22)0.371.35 (1.09, 1.66)<0.011.41 (1.21, 1.78)<0.01——1.08 (0.91, 1.27)0.39
    Corrected serum calcium1.03 (0.86, 1.22)0.791.04 (0.79, 1.38)0.760.95 (0.70, 1.31)0.77——0.93 (0.75, 1.15)0.51
    Total iPTH——1.00 (1.00, 1.00)0.431.00 (1.00, 1.00)0.63————
    • CAC, coronary artery calcium; CVD, cardiovascular disease; LVH, left ventricular hypertrophy; ABI, ankle-brachial index; CI, confidence interval; OR, odds ratio; NH, non-Hispanic; eGFR, estimated glomerular filtration rate; HS, high school; BP, blood pressure; Hs-CRP, high-sensitivity C-reactive protein; SD, standard deviation; iPTH, intact parathyroid hormone; BMI, body mass index.

    • a Adjusted for age, gender, education, and clinical site.

    • b Additionally adjusted for all variables listed. CVD, CAC, and ABI models were additionally adjusted for serum phosphate and calcium. Intact PTH (iPTH) was only analyzed in the CAC models.

    • View popup
    Table 5.

    Achievement of guideline-recommended goals for secondary prevention of CVD among participants with any self-reported CVD at baseline

    VariablesHispanic n = 138Non-Hispanic Caucasian n = 507Non-Hispanic African American n = 627
    n (%)n (%)Pn (%)P
    Not current smoker132 (96)454 (90)0.03488 (78)<0.01
    BP <130/80 mmHG55 (40)316 (62)<0.01244 (39)0.84
    LDL ≤100101 (73)361 (71)0.65352 (56)<0.01
    Physical activity 30 min/day, at least 5 d/wk51 (39)257 (53)<0.01259 (44)0.23
    BMI <25 kg/m213 (9)74 (15)0.1276 (12)0.37
    Waist circumference: men <40 in, women <35 in47 (35)154 (31)0.35138 (22)<0.01
    Hg A1C <7%54 (39)313 (62)<0.01333 (53)<0.01
    Aspirin use66 (48)343 (68)<0.01363 (58)0.03
    RAS blocker use100 (73)397 (79)0.13479 (77)0.30
    β-blocker use104 (76)346 (69)0.11452 (73)0.40
    • BMI, body mass index; Hg, hemoglobin; RAS, renin-angiotensin system.

PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 6 (9)
Clinical Journal of the American Society of Nephrology
Vol. 6, Issue 9
1 Sep 2011
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Cardiovascular Disease Among Hispanics and Non-Hispanics in the Chronic Renal Insufficiency Cohort (CRIC) Study
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Cardiovascular Disease Among Hispanics and Non-Hispanics in the Chronic Renal Insufficiency Cohort (CRIC) Study
Ana C. Ricardo, James P. Lash, Michael J. Fischer, Claudia M. Lora, Matthew Budoff, Martin G. Keane, John W. Kusek, Monica Martinez, Lisa Nessel, Thomas Stamos, Akinlolu Ojo, Mahboob Rahman, Elsayed Z. Soliman, Wei Yang, Harold I. Feldman, Alan S. Go
CJASN Sep 2011, 6 (9) 2121-2131; DOI: 10.2215/CJN.11341210

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Cardiovascular Disease Among Hispanics and Non-Hispanics in the Chronic Renal Insufficiency Cohort (CRIC) Study
Ana C. Ricardo, James P. Lash, Michael J. Fischer, Claudia M. Lora, Matthew Budoff, Martin G. Keane, John W. Kusek, Monica Martinez, Lisa Nessel, Thomas Stamos, Akinlolu Ojo, Mahboob Rahman, Elsayed Z. Soliman, Wei Yang, Harold I. Feldman, Alan S. Go
CJASN Sep 2011, 6 (9) 2121-2131; DOI: 10.2215/CJN.11341210
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

Original Articles

  • Association of Polypharmacy with Kidney Disease Progression in Adults with CKD
  • The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function
  • Collectin11 and Complement Activation in IgA Nephropathy
Show more Original Articles

Chronic Kidney Disease

  • PCSK9 and Cardiovascular Disease in Individuals with Moderately Decreased Kidney Function
  • Apolipoprotein L1 High-Risk Genotypes and Albuminuria in Sub-Saharan African Populations
  • Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection
Show more Chronic Kidney Disease

Cited By...

  • Statistical Methods for Cohort Studies of CKD: Survival Analysis in the Setting of Competing Risks
  • CKD Progression and Mortality among Hispanics and Non-Hispanics
  • Associations of Left Ventricular Hypertrophy and Geometry with Adverse Outcomes in Patients with CKD and Hypertension
  • Trends in the Incidence of Atrial Fibrillation in Older Patients Initiating Dialysis in the United States
  • Associations between Kidney Function and Subclinical Cardiac Abnormalities in CKD
  • Hispanic Ethnicity and Vascular Access Use in Patients Initiating Hemodialysis in the United States
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals

© 2022 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire